Pharmaceutical - AstraZeneca, Pharmaceutical

Filter

Current filters:

AstraZenecaPharmaceutical

Popular Filters

1 to 25 of 310 results

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Roche could lose its dominant market share in breast cancer, says IMS report

Roche could lose its dominant market share in breast cancer, says IMS report

03-10-2014

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs,…

AstraZenecaGlobalHerceptinMarkets & MarketingNovartisOncologyPharmaceuticalRochetamoxifen

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

01-10-2014

The annual congress of the European Society for Medical Oncology (ESMO) came to a close in Madrid, Spain,…

AstraZenecaAZD9291IressaOncologyPharmaceuticalResearchUK

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

Almirall’s aclidinium bromide/formoterol backed by EMA/CHMP to treat COPD

Almirall’s aclidinium bromide/formoterol backed by EMA/CHMP to treat COPD

26-09-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a…

aclidiniumAlmirallAstraZenecaBrimica GenuairDuaklir GenuairEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

FDA approves AstraZeneca’s Movantik for opioid-induced constipation

FDA approves AstraZeneca’s Movantik for opioid-induced constipation

17-09-2014

The US Food and Drug Administration yesterday approved Movantik (naloxegol), an oral treatment for opioid-induced…

AstraZenecaGastro-intestinalsMovantikNektar TherapeuticsPharmaceuticalRegulationUSA

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

Redx Pharma and AstraZeneca collaborate on oncology research

04-09-2014

UK-based drug discovery firm Redx Pharma says it has entered into a research collaboration with Anglo-Swedish…

AstraZenecaOncologyPharmaceuticalRedx PharmaResearch

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

28-08-2014

Research by Anglo-Swedish drug major AstraZeneca into the cost burden of cardiovascular disease has shown…

AstraZenecaCardio-vascularEconomy of the European UnionEuropePharmaceuticalResearch

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

22-08-2014

While speculation continues as to whether Pfizer will resume its attempts to buy AstraZeneca, Pfizer…

ActavisAstraZenecaBusiness FinanceIrelandMergers & AcquisitionsPfizerPharmaceuticalSwedenUKUnited StatesUSA

AstraZeneca and Mitsubishi Tanabe Pharma to collaborate on diabetic nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma to collaborate on diabetic nephropathy

20-08-2014

Anglo-Swedish drug major AstraZeneca has entered into a three-year research collaboration on diabetic…

AstraZenecaChronic kidney diseaseDiabetesJapanKidney diseasesMitsubishi TanabeNephrology and HepatologyPharmaceuticalResearchSweden

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

AstraZeneca reports positive results from lesinurad trial for gout

AstraZeneca reports positive results from lesinurad trial for gout

13-08-2014

Anglo-Swedish drug major AstraZeneca has said its Phase III trials of lesinurad in combination with xanthine…

AstraZenecaEuropeGastro-intestinalslesinuradPharmaceuticalResearchSymptomatic gout

NICE comes back with different views on Tarceva and Iressa for NSCLC

NICE comes back with different views on Tarceva and Iressa for NSCLC

07-08-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is consulting again…

AstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

AstraZeneca 2nd-qtr earnings leap, beating expectations

AstraZeneca 2nd-qtr earnings leap, beating expectations

31-07-2014

Anglo-Swedish pharma major AstraZeneca, which earlier this year defended itself against an unsolicited…

AstraZenecaBusiness FinanceFinancialPharmaceuticalUK

1 to 25 of 310 results

Back to top